Evaluation of 177Lu-Psma-617 SPECT/CT Quantitation As a Response Biomarker Within a Prospective 177Lu-Psma-617 and NOX66 Combination Trial (Lupin).
JOURNAL OF NUCLEAR MEDICINE(2023)
关键词
metastatic prostate cancer,SPECT,lutetium-PSMA,response biomarker
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要